SCHEMBL856794

SCHEMBL856794

CC(C)(C)OC(=O)C(N)CCN

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS1 P29475 2/20 0.40
NOS3 P29474 1/20 0.40
NOS2 P35228 1/20 0.40
LTA4H P09960 1/20 0.39
DPP7 Q9UHL4 4/20 0.37
RRM1 P23921 1/20 0.36
GABRR1 P24046 2/20 0.35
DPP8 Q6V1X1 2/20 0.33
DPP9 Q86TI2 2/20 0.33
GSR P00390 1/20 0.33
MEN1 O00255 1/20 0.33
GAA P10253 1/20 0.33
KMT2A Q03164 1/20 0.33
CYP3A4 P08684 2/20 0.33
SLC7A5 Q01650 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 1/20 0.33
NFKB1 P19838 1/20 0.33
CYP2C19 P33261 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30860145 1.00 NOS1 (0.40) NOS1NOS3NOS2LTA4HDPP7
SCHEMBL30471715 1.00 NOS1 (0.40) NOS1NOS3NOS2LTA4HDPP7
Hydrochloric Acid SCHEMBL5821232 0.98 NOS1 (0.39) NOS1NOS3NOS2LTA4HDPP7
SCHEMBL3294154 0.89 NOS1 (0.42) NOS1NOS3NOS2LTA4HMEN1
SCHEMBL11415214 0.88 GSR (0.44) NOS1NOS3NOS2LTA4HDPP7
SCHEMBL11415211 0.88 GSR (0.44) NOS1NOS3NOS2LTA4HDPP7
SCHEMBL855007 0.88 GSR (0.44) NOS1NOS3NOS2LTA4HDPP7
SCHEMBL855342 0.86 GSR (0.52) NOS1NOS3NOS2LTA4HDPP7
Hydrochloric Acid SCHEMBL11272393 0.86 GSR (0.42) NOS1NOS3NOS2LTA4HDPP7
SCHEMBL866977 0.86 GSR (0.52) NOS1NOS3NOS2LTA4HDPP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 216 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024221952-A1 NANO-DELIVERY SYSTEM OF NUCLEOTIDE DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF 中国科学院苏州纳米技术与纳米仿生研究所 2024-10-31 WO claimed
CN-106750252-B Distearoylphosphatidylethanolamine-polyethylene glycol 2000- double leaf acid and its preparation method and application 山东大学齐鲁医院 2018-11-30 CN claimed
CN-106750252-A DSPE polyethylene glycol 2000 double leaf acid and its preparation method and application 山东大学齐鲁医院 2017-05-31 CN claimed
EP-1532444-A2 METHOD FOR ANALYZING BODY FLUIDS FOR THE PRESENCE OF CANCER CELLS AND CORRESPONDING ANALYSIS KITS Giesing, Michael, Prof. Dr. med. (DE) 2005-05-25 EP claimed
WO-2004019037-A2 METHOD FOR ANALYZING BODY FLUIDS FOR THE PRESENCE OF CANCER CELLS, USE THEREOF, CORRESPONDING ANALYSIS KITS, AND USE OF SPECIFIC ACTIVE SUBSTANCES FOR TREATING CANCER GIESING MICHAEL (DE) 2004-03-04 WO claimed
CN-122080114-A Composition containing long-chain alkane for polypeptide synthesis and preparation method of polypeptide 2026-05-26 CN disclosed
US-20250387492-A1 HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF FUSION PHARMACEUTICALS INC (CA) 2025-12-25 US disclosed
US-20250353872-A1 Ligand-Modified Oligonucleotides NOVO NORDISK A/S (DK) 2025-11-20 US disclosed
EP-4572758-A1 PROTEIN:PROTEIN INTERACTION INHIBITORS Purdue Research Foundation (US) 2025-06-25 EP disclosed
CN-119859122-B Tyrosinase inhibitor and preparation method and application thereof 杭州师范大学 2025-06-13 CN disclosed
CN-119859122-A Tyrosinase inhibitor and preparation method and application thereof 杭州师范大学 2025-04-22 CN disclosed
EP-4526303-A1 N6-ADENOSINE-METHYLTRANSFERASE PROTACS AND METHODS OF USE THEREOF University of Zurich (CH) 2025-03-26 EP disclosed
WO-2001016162-A1 METHOD FOR PRODUCING CYCLIC PEPTIDOMIMETICS CHEMOTOPIX GMBH (DE) 2001-03-08 WO disclosed
WO-1999050244-A9 NITROXIDE FREE RADICAL DUAL INDICATOR AGENTS LIPITEK INC (US) 1999-12-09 WO disclosed
WO-1999050244-A1 NITROXIDE FREE RADICAL DUAL INDICATOR AGENTS LIPITEK, INC. (US) 1999-10-07 WO disclosed
EP-0938497-A1 CONSTRAINED HELICAL PEPTIDES AND METHODS OF MAKING SAME Genentech, Inc. (US) 1999-09-01 EP disclosed
EP-0874841-A1 1-BENZENESULFONYL PYRROLIDINE DERIVATIVES AS BRADYKININ RECEPTOR B2 ANTAGONISTS FOURNIER INDUSTRIE ET SANTE (FR) 1998-11-04 EP disclosed
WO-1998020036-A1 CONSTRAINED HELICAL PEPTIDES AND METHODS OF MAKING SAME GENENTECH, INC. (US) 1998-05-14 WO disclosed
WO-1997024349-A1 1-BENZENESULFONYL PYRROLIDINE DERIVATIVES AS BRADYKININ RECEPTOR ANTAGONISTS FOURNIER INDUSTRIE ET SANTE (FR) 1997-07-10 WO disclosed
US-4766110-A INHIBITS ANGIOTENSIN CONVERTING ENZYME, HYPOTENSIVE AGENTS RYAN JAMES W (US) 1988-08-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250353872-A1 Ligand-Modified Oligonucleotides NCL, ADAR, NSUN3 NOS1 4148/4885NOS3 3687/4885NOS2 4166/4885
US-20250387492-A1 HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF HSP90AB1, HSP90AB2P, HSP90AA1 NOS1 3589/4885NOS3 2871/4885NOS2 2679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.